Berkshire Hathaway (BRK.A -0.33%) (BRK.B -0.11%) will likely report first-quarter 2025 earnings on or around May 2. You might want to buy it before that date even if you have the same question on your mind as everyone else.

Nvidia (NASDAQ: NVDA) is up over 18,000% in the last 10 years. It is one of the best-performing stocks in the world during that time and is now the third-largest company in the world by market capitalization.

The Trump administration's ambitious tariff actions (and threats) have set off a level of volatility in the U.S. stock market that investors haven't seen since the pandemic. The market has not officially crashed, but it appears that the artificial intelligence (AI)-driven market rally that began in early 2023 has come to an end.

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of Cancer Research (AACR) Annual Meeting being held on April 25-30, 2025 in Chicago, IL.

The market is not favoring artificial intelligence (AI) stocks right now, as it is trying to de-risk itself by selling off the high-growth names that need prime economic conditions to succeed. This has opened up an opportunity to snag some of the top-performing AI stocks at a huge discount, and if you're patient, these stocks could easily crush the market over the next few years.

I rate WEC a Buy due to its strategic alignment in AI-driven energy demand and clean energy transition, positioning it for long-term growth. WEC plans a $28 billion investment from 2025-2029 to expand load capacity, reliability, and renewable energy, driving significant growth. Key projects include a $3.3 billion AI data center by Microsoft and a 1 GW data center in Wisconsin, boosting demand by 20%.

Because of how well it represents the performance of the overall stock market, investors seem to always have their eyes on the S&P 500 index. This benchmark contains some of the largest and most profitable companies in the U.S. Despite its solid long-term track record, it has been under pressure in the past couple months due to economic worries.

FATN has a subscription-based SD-WAN, SASE, and NMS suite that's built on patented MPVPN/MPSec bonding engines. The company went public in April 2025 at $5.75 per share, which has now more than doubled to roughly $11.35. While they distribute their suite of network solutions through several partners, in reality just two of them account for 49.5% of total revenues, indicating some revenue concentration risks.

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline.

Gold prices rally on political risks and economic fears. Upcoming Core PCE and non-farm payrolls could determine the gold market's next breakout.

Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also begun in the ASCEND CSP pivotal clinical trial to evaluate Abbott's investigational CSP Implantable Cardioverter-Defibrillator (ICD) lead Conduction System Pacing is an evolving technique specifically designed to deliver pacing to the left bundle branch area of the heart to restore its natural electrical rhythm SAN DIEGO , April 27, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the AVEIR™ Conduction System Pacing (CSP) acute clinical feasibility study, which demonstrated the safety and performance of …

Amid hype over artificial intelligence, the best AI stocks generate revenue or get a strategic edge from the fast evolving technology.

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Bancorp, Inc. (NASDAQ: TBBK) between January 25, 2024 and March 4, 2025, both dates inclusive (the “Class Period”), of the important May 16, 2025 lead plaintiff deadline.

Everyone is looking for an edge in the market. With earnings season underway, Rockland Trust vice president and portfolio manager Karl Farmer shares three stocks he is keeping an eye on.

About a third of the S&P 500 index reports earnings this week. Plus economic data on inflation, GDP, and jobs.

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72 HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research® (AACR) Annual Meeting …

After warning during its fourth-quarter conference call that 2025 was off to a tough start in January, fast-casual restaurant chain Chipotle Mexican Grill (CMG 4.84%) found that traffic never really recovered; it reported its first same-store sales decline since 2020, early in the COVID-19 pandemic. The stock largely shrugged off these disappointing results, although as of this writing it's still down more than 18% on the year.

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.

Crude oil futures face mounting pressure as supply surplus fears grow. Traders prepare for more downside risks unless new bullish drivers emerge.

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.